CN109789210A - 用于治疗癌症的胰高血糖素受体拮抗剂和pi3k途径抑制剂的组合 - Google Patents

用于治疗癌症的胰高血糖素受体拮抗剂和pi3k途径抑制剂的组合 Download PDF

Info

Publication number
CN109789210A
CN109789210A CN201780061812.9A CN201780061812A CN109789210A CN 109789210 A CN109789210 A CN 109789210A CN 201780061812 A CN201780061812 A CN 201780061812A CN 109789210 A CN109789210 A CN 109789210A
Authority
CN
China
Prior art keywords
body weight
week
day
antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780061812.9A
Other languages
English (en)
Chinese (zh)
Inventor
弗兰克·J·卡尔佐内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rui Virtues Bio Medicine Technology Co Ltd
Original Assignee
Rui Virtues Bio Medicine Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rui Virtues Bio Medicine Technology Co Ltd filed Critical Rui Virtues Bio Medicine Technology Co Ltd
Publication of CN109789210A publication Critical patent/CN109789210A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201780061812.9A 2016-08-03 2017-08-03 用于治疗癌症的胰高血糖素受体拮抗剂和pi3k途径抑制剂的组合 Pending CN109789210A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370642P 2016-08-03 2016-08-03
US62/370,642 2016-08-03
PCT/US2017/045390 WO2018027084A2 (en) 2016-08-03 2017-08-03 Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN109789210A true CN109789210A (zh) 2019-05-21

Family

ID=61073805

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780061812.9A Pending CN109789210A (zh) 2016-08-03 2017-08-03 用于治疗癌症的胰高血糖素受体拮抗剂和pi3k途径抑制剂的组合

Country Status (8)

Country Link
US (1) US11319376B2 (https=)
EP (1) EP3493847A4 (https=)
JP (1) JP7187035B2 (https=)
CN (1) CN109789210A (https=)
AU (1) AU2017305502B2 (https=)
CA (1) CA3036273A1 (https=)
MX (1) MX2019001467A (https=)
WO (1) WO2018027084A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114096249A (zh) * 2019-07-09 2022-02-25 奥瑞克索股份公司 用于鼻腔递送的药物组合物
CN114729050A (zh) * 2019-11-21 2022-07-08 百济神州有限公司 使用抗OX40抗体与PI3激酶δ抑制剂组合治疗癌症的方法
CN114958771A (zh) * 2022-06-27 2022-08-30 广东康盾创新产业集团股份公司 一种ipsc-car-nk细胞的制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3239447A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
JP2022512826A (ja) * 2018-10-26 2022-02-07 シンデブルックス，インコーポレイティド ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102958518A (zh) * 2009-05-15 2013-03-06 诺瓦提斯公司 磷脂酰肌醇3-激酶抑制剂和抗糖尿病化合物的组合
CN103998935A (zh) * 2011-04-28 2014-08-20 斯隆-凯特林癌症研究所 Hsp90组合疗法
WO2015189698A2 (en) * 2014-06-08 2015-12-17 Beijing Cosci-Remd Bio Med Tech Company Ltd Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102958518A (zh) * 2009-05-15 2013-03-06 诺瓦提斯公司 磷脂酰肌醇3-激酶抑制剂和抗糖尿病化合物的组合
CN103998935A (zh) * 2011-04-28 2014-08-20 斯隆-凯特林癌症研究所 Hsp90组合疗法
WO2015189698A2 (en) * 2014-06-08 2015-12-17 Beijing Cosci-Remd Bio Med Tech Company Ltd Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114096249A (zh) * 2019-07-09 2022-02-25 奥瑞克索股份公司 用于鼻腔递送的药物组合物
CN114729050A (zh) * 2019-11-21 2022-07-08 百济神州有限公司 使用抗OX40抗体与PI3激酶δ抑制剂组合治疗癌症的方法
CN114958771A (zh) * 2022-06-27 2022-08-30 广东康盾创新产业集团股份公司 一种ipsc-car-nk细胞的制备方法
CN114958771B (zh) * 2022-06-27 2023-12-05 广东康盾创新产业集团股份公司 一种ipsc-car-nk细胞的制备方法

Also Published As

Publication number Publication date
CA3036273A1 (en) 2018-02-08
WO2018027084A3 (en) 2018-03-29
MX2019001467A (es) 2019-10-02
EP3493847A4 (en) 2020-04-08
AU2017305502A1 (en) 2019-03-21
EP3493847A2 (en) 2019-06-12
WO2018027084A2 (en) 2018-02-08
JP2019527697A (ja) 2019-10-03
JP7187035B2 (ja) 2022-12-12
US11319376B2 (en) 2022-05-03
US20190169300A1 (en) 2019-06-06
AU2017305502B2 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
JP7212902B2 (ja) 疾患および障害の処置においてレナラーゼを制御する組成物および方法
CN109789210A (zh) 用于治疗癌症的胰高血糖素受体拮抗剂和pi3k途径抑制剂的组合
CN106977606B (zh) 结合egfr和c-met iii型纤连蛋白域的分子
JP2023539715A (ja) 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
TWI513465B (zh) 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
PT2752189T (pt) Utilização de anticorpos anti-fcev em combinação com quimioterpia para o tratamento de cancro da mama
JP2016509045A (ja) がんを治療し、薬剤耐性を防止する方法
CN103890007A (zh) 神经调节蛋白抗体及其用途
CN106659788A (zh) 治疗和预防癌症耐药性的方法
JP7148151B2 (ja) 抗レナラーゼ抗体および抗ｐｄ－１抗体を用いる、がんを処置するための組成物および方法
US20250228858A1 (en) Anti-cancer combination therapy
KR20210053242A (ko) 항암제 내성을 완화하고 항암제의 민감성을 강화하기 위한 약학적 조성물 및 그 용도
TW202432142A (zh) 治療癌症之組合療法
CN111886257A (zh) 用于疾病和病症治疗和预防的抗-肾酶抗体
US20260034134A1 (en) Treatment of cancer with metastases in the central nervous system
WO2024263963A2 (en) Compositions comprising antineoplastons and methods of treating head and neck cancer
TW202448508A (zh) 治療癌症之方法及組成物
CA2953807C (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
EP4727534A1 (en) Compositions comprising antineoplastons and methods of treating breast cancer
TW202539731A (zh) 用抗ＦｃＲＨ５／抗ＣＤ３雙特異性抗體治療癌症之治療及診斷方法
HK40102568A (zh) 用於使用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物的治疗的给药
HK1226956A1 (en) Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190521